Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations.

Choi JH, Stubblefield B, Cookson MR, Goldin E, Velayati A, Tayebi N, Sidransky E.

Mol Genet Metab. 2011 Sep-Oct;104(1-2):185-8. doi: 10.1016/j.ymgme.2011.06.008. Epub 2011 Jun 17.

2.

Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies.

Sardi SP, Clarke J, Viel C, Chan M, Tamsett TJ, Treleaven CM, Bu J, Sweet L, Passini MA, Dodge JC, Yu WH, Sidman RL, Cheng SH, Shihabuddin LS.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3537-42. doi: 10.1073/pnas.1220464110. Epub 2013 Jan 7.

3.

Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.

Sardi SP, Singh P, Cheng SH, Shihabuddin LS, Schlossmacher MG.

Neurodegener Dis. 2012;10(1-4):195-202. doi: 10.1159/000335038. Epub 2012 Feb 9. Review.

PMID:
22327140
4.

Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders.

Goker-Alpan O, Stubblefield BK, Giasson BI, Sidransky E.

Acta Neuropathol. 2010 Nov;120(5):641-9. doi: 10.1007/s00401-010-0741-7. Epub 2010 Sep 14.

5.

Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle.

Sardi SP, Cheng SH, Shihabuddin LS.

Prog Neurobiol. 2015 Feb;125:47-62. doi: 10.1016/j.pneurobio.2014.12.001. Epub 2015 Jan 6. Review.

6.

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease.

Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, Cooper A, Garner B, Halliday GM.

Brain. 2014 Mar;137(Pt 3):834-48. doi: 10.1093/brain/awt367. Epub 2014 Jan 28.

7.

CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.

Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, Passini MA, Grabowski GA, Schlossmacher MG, Sidman RL, Cheng SH, Shihabuddin LS.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12101-6. doi: 10.1073/pnas.1108197108. Epub 2011 Jul 5.

8.

Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.

Yang NY, Lee YN, Lee HJ, Kim YS, Lee SJ.

Biol Chem. 2013 Jul;394(7):807-18. doi: 10.1515/hsz-2012-0322. Review.

PMID:
23435096
9.

Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death.

Keatinge M, Bui H, Menke A, Chen YC, Sokol AM, Bai Q, Ellett F, Da Costa M, Burke D, Gegg M, Trollope L, Payne T, McTighe A, Mortiboys H, de Jager S, Nuthall H, Kuo MS, Fleming A, Schapira AH, Renshaw SA, Highley JR, Chacinska A, Panula P, Burton EA, O'Neill MJ, Bandmann O.

Hum Mol Genet. 2015 Dec 1;24(23):6640-52. doi: 10.1093/hmg/ddv369. Epub 2015 Sep 16.

10.

The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism.

DePaolo J, Goker-Alpan O, Samaddar T, Lopez G, Sidransky E.

Mov Disord. 2009 Aug 15;24(11):1571-8. doi: 10.1002/mds.22538. Review.

11.

Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.

Rocha EM, Smith GA, Park E, Cao H, Brown E, Hayes MA, Beagan J, McLean JR, Izen SC, Perez-Torres E, Hallett PJ, Isacson O.

Neurobiol Dis. 2015 Oct;82:495-503. doi: 10.1016/j.nbd.2015.09.009. Epub 2015 Sep 25.

12.

Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.

Rocha EM, Smith GA, Park E, Cao H, Graham AR, Brown E, McLean JR, Hayes MA, Beagan J, Izen SC, Perez-Torres E, Hallett PJ, Isacson O.

Antioxid Redox Signal. 2015 Aug 20;23(6):550-64. doi: 10.1089/ars.2015.6307. Epub 2015 Jul 29.

13.

Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.

Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E.

Neurology. 2006 Sep 12;67(5):908-10. Epub 2006 Jun 21.

PMID:
16790605
14.

Parkinsonism, dementia and glucocerebrosidase mutations.

Peall K, Robertson NP.

J Neurol. 2013 May;260(5):1441-4. doi: 10.1007/s00415-013-6923-1. No abstract available.

PMID:
23620067
15.

Exploring the link between glucocerebrosidase mutations and parkinsonism.

Westbroek W, Gustafson AM, Sidransky E.

Trends Mol Med. 2011 Sep;17(9):485-93. doi: 10.1016/j.molmed.2011.05.003. Epub 2011 Jul 1. Review.

16.

Emerging insights into the mechanistic link between α-synuclein and glucocerebrosidase in Parkinson's disease.

McGlinchey RP, Lee JC.

Biochem Soc Trans. 2013 Dec;41(6):1509-12. doi: 10.1042/BST20130158.

17.

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, Dardis A, Deganuto M, De Carlo C, Castrioto A, Balducci C, Paciotti S, Tambasco N, Bembi B, Bonanni L, Onofrj M, Rossi A, Beccari T, El-Agnaf O, Calabresi P.

Mov Disord. 2014 Jul;29(8):1019-27. doi: 10.1002/mds.25772. Epub 2014 Jan 16.

18.

Saposin C protects glucocerebrosidase against α-synuclein inhibition.

Yap TL, Gruschus JM, Velayati A, Sidransky E, Lee JC.

Biochemistry. 2013 Oct 15;52(41):7161-3. doi: 10.1021/bi401191v. Epub 2013 Oct 1.

19.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

PMID:
19903734
20.

Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.

Blanz J, Saftig P.

J Neurochem. 2016 Oct;139 Suppl 1:198-215. doi: 10.1111/jnc.13517. Epub 2016 Feb 10. Review.

PMID:
26860955

Supplemental Content

Support Center